Skip to content

Study · Non-randomized trial · n = 22 · 2025

2 results

The pharmacokinetics and comparative bioavailabilty of oral and subcutaneous semaglutide in healthy volunteers.

Bouhajib M, Tayab Z, Di Marco C, Suh DD

Journal of basic and clinical physiology and pharmacology1 Mar 2025Cited by 1 (Europe PMC)

PMID40425315 (opens in a new tab)DOI10.1515/jbcpp-2025-0026 (opens in a new tab)PepBankPUB-40425315
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In healthy volunteers, oral semaglutide 3 mg had a relative bioavailability of 0.66 % compared with subcutaneous semaglutide 0.25 mg.

    In plain wordsIn healthy volunteers, the oral semaglutide dose reached the blood at 0.66 % of the level of the injected dose.

    Peptide
    Semaglutide
    Outcome
    Not applicableRelative bioavailability of oral versus subcutaneous semaglutide
    Study

    n = 22

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.25 mg SC; 3 mg PO · subcutaneous and oralAs given in this study (human).

    Measurements

    Relative bioavailability (PO relative to SC)
    0.66%
    3 mg PO versus 0.25 mg SC

    Source sentences

    Summary
    The comparative bioavailability (PO relative to SC) was 0.66 % at the doses administered.
    1 context sentence
    Summary · context
    Twenty-two subjects were administered either 0.25 mg SC or 3 mg PO and blood samples were taken up to 504 h.
  2. 02HumanNon-randomized trialSafety outcome

    In healthy volunteers, single low doses of oral and subcutaneous semaglutide were well tolerated and no serious adverse events were reported.

    In plain wordsIn healthy volunteers, low oral and injected semaglutide doses were well tolerated, with no serious side effects reported.

    Peptide
    Semaglutide
    Outcome
    No significant changeTolerability and serious adverse events
    Study

    n = 22

    Outcome group
    Adverse events · Whole body
    Studied dose
    0.25 mg SC; 3 mg PO · subcutaneous and oralAs given in this study (human).

    Source sentences

    Summary
    Overall, the study drug was well tolerated, and no serious adverse events were reported.
    1 context sentence
    Summary · context
    Twenty-two subjects were administered either 0.25 mg SC or 3 mg PO and blood samples were taken up to 504 h.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.